Table 3

Grade assessment of FeNO-based papers

Graphic
  • GRADE Working Group grades of evidence.

  • High quality: further research is very unlikely to change our confidence in the estimate of effect.

  • Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

  • Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

  • Very low quality: we are very uncertain about the estimate.

  • *The basis for the assumed risk (eg, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

  • 1 CIs are wide and include clinically important benefit and harm.

  • 2 One study (deJongste 2008) design was open label which may have introduced bias.

  • 3 Studies reported technical difficulties with FeNO analyses as reported in risk of bias table.

  • 4 Medication increased prior to commencement of study.

  • 5 In one study the overall dose of ICS was higher with FeNO-based interventions even though the final ICS dose was lower.

  • 6 One study presented in these results was single blinded with the intervention arm analysing FeNO only.

  • 7 Final ICS doses were quite varied, with one study having particularly high doses.

  • FeNO, fractional expired nitric oxide; ICS, inhaled corticosteroid.